Subscribe free

Intestine and Lower Gastrointestinal Tract ·

High Endoscopic Cuffitis Rates Post-Ileal Pouch-Anal Anastomosis: Association with Extensive Disease and Biologic Exposure

Endoscopic cuffitis occurred in approximately 60% of patients who underwent restorative proctocolectomy with stapled ileal pouch–anal anastomosis, and was significantly associated with extensive disease and exposure to multiple biologics before colectomy. Older age, extensive disease, exposure to biologics before colectomy, and exposure to at least 2 or more biologics before colectomy were all significantly associated with subsequent cuffitis post-ileal pouch-anal anastomosis in patients with ulcerative colitis.

Journal Article by Posner H, Lombard R (…) Kayal M et 5 al. in Inflamm Bowel Dis

© The Author(s) 2024. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
© The Author(s) 2024. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

read the whole article in Inflamm Bowel Dis

open it in PubMed

Summaries are written to help you decide what to read. They do not replace the full paper.

Free · 5 minutes a day

Get every new paper in Intestine and Lower Gastrointestinal Tract.

Plus the Daily Selection: the five most relevant papers of the day, each cut to its key points.

Specialty newsletters: every new paper in your field, as a list of titles linked to the source. Daily Selection: the five that matter, cut to their key points.

FreeNo spamOne-click unsubscribe

More in Intestine and Lower Gastrointestinal Tract

The latest stitches

Br J Surg5 Nov 2026

Rectal cancer and liver spread: similar outcomes

Removing the rectal tumor and liver spread in one operation did not clearly raise complications or hurt survival compared with two separate operations, a French national study found.

Lancet4 Nov 2026

Colorectal cancer: shorter chemo, fewer side effects

A Japanese randomized trial found that a 14-day schedule of trifluridine-tipiracil plus bevacizumab keeps patients with metastatic colorectal cancer alive as long as the standard 28-day schedule, with far less toxicity.

All papers in Intestine and Lower Gastrointestinal Tract →